1. A class action was filed against ZBIO regarding its IPO disclosures. 2. Allegations suggest ZBIO misled investors about its operational funding timeline. 3. ZBIO's share price fell 48.7% since its IPO due to these disclosures. 4. Shareholders may participate as lead plaintiffs in the class action. 5. Legal representation operates on a contingency fee basis.
The significant drop in share price indicates investor loss of confidence, similar cases have historically led to continued declines until clarity is restored.
The ongoing class action can influence ZBIO's reputation and financial stability, leading to investor caution.
The immediate impact from the lawsuit can lead to volatility, with potential further declines as legal proceedings unfold.
Robbins LLP reminds stockholders that a class action was filed on behalf of all persons who purchased or otherwise acquired Zenas BioPharma, Inc. (NASDAQ: ZBIO) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma's September 2024 initial public offering. Zenas BioPharma purports to be a "clinical stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need."
For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.
Robbins LLP is Investigating Allegations that Zenas BioPharma, Inc. (ZBIO) Misled Investors in Connection with its IPO.
According to the complaint, defendants failed to disclose that in connection with its IPO, Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO. On November 12, 2024, the Company filed with the SEC its quarterly report on Form 10-Q for the period ended September 30, 2024, stating that the Company could fund its operations for the following twelve months, not twenty-four, as it had stated in the Registration Statement. Since the IPO, and as a result of the disclosure of material adverse facts omitted from Zenas BioPharma's Registration Statement, Zenas BioPharma's share price has fallen substantially below its IPO price. As of the close of trading on April 15, 2025, the closing price of Zenas BioPharma stock was $8.72, 48.7% below the IPO price.
You may be eligible to participate in the class action against Zenas BioPharma, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 16, 2025. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002.
To be notified if a class action against Zenas BioPharma, Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
SOURCE Robbins LLP